144 related articles for article (PubMed ID: 30863099)
1. Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.
Yu D; Han G; Liu H; Gao L; Verma V
Onco Targets Ther; 2019; 12():1333-1339. PubMed ID: 30863099
[TBL] [Abstract][Full Text] [Related]
2. Adult isocitrate dehydrogenase-mutant brainstem glioma: illustrative case.
Ye VC; Landry AP; Purzner T; Kalyvas A; Mohan N; O'Halloran PJ; Gao A; Zadeh G
J Neurosurg Case Lessons; 2021 Mar; 1(12):CASE2078. PubMed ID: 35854925
[TBL] [Abstract][Full Text] [Related]
3. Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Zhu Y; Zhao L; Xu Y; Zhan W; Sun X; Xu X
Ann Palliat Med; 2022 Jan; 11(1):394-400. PubMed ID: 35144430
[TBL] [Abstract][Full Text] [Related]
4. Case report of a
Luo C; Shen J; Ying J; Fang X; Wang X; Fu Z; Liu P
Onco Targets Ther; 2017; 10():4553-4557. PubMed ID: 29066909
[TBL] [Abstract][Full Text] [Related]
5. Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review.
Wang Y; He Q; Meng X; Zhou S; Zhu Y; Xu J; Tao R
World Neurosurg; 2019 Apr; 124():319-322. PubMed ID: 30639490
[TBL] [Abstract][Full Text] [Related]
6. Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report.
Morimoto T; Matsuda R; Nakazawa T; Nishimura F; Nakagawa I
Brain Tumor Res Treat; 2022 Apr; 10(2):129-133. PubMed ID: 35545834
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series.
Zhang H; Chen F; Wang Z; Wu S
Onco Targets Ther; 2017; 10():837-845. PubMed ID: 28243119
[TBL] [Abstract][Full Text] [Related]
8. Brainstem gliomas in adults: prognostic factors and classification.
Guillamo JS; Monjour A; Taillandier L; Devaux B; Varlet P; Haie-Meder C; Defer GL; Maison P; Mazeron JJ; Cornu P; Delattre JY;
Brain; 2001 Dec; 124(Pt 12):2528-39. PubMed ID: 11701605
[TBL] [Abstract][Full Text] [Related]
9. Adult brainstem gliomas: Correlation of clinical and molecular features.
Theeler BJ; Ellezam B; Melguizo-Gavilanes I; de Groot JF; Mahajan A; Aldape KD; Bruner JM; Puduvalli VK
J Neurol Sci; 2015; 353(1-2):92-7. PubMed ID: 25934342
[TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
11. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
Broniscer A; Gajjar A
Oncologist; 2004; 9(2):197-206. PubMed ID: 15047924
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy in supratentorial gliomas. A study of 821 cases.
Heesters M; Molenaar W; Go GK
Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126
[TBL] [Abstract][Full Text] [Related]
13. Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review.
Li X; Chai J; Wang Z; Lu L; Zhao Q; Zhou J; Ju F
Onco Targets Ther; 2018; 11():4407-4411. PubMed ID: 30104882
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases.
Yoshimura J; Onda K; Tanaka R; Takahashi H
Neurol Med Chir (Tokyo); 2003 Aug; 43(8):375-82; discussion 382. PubMed ID: 12968803
[TBL] [Abstract][Full Text] [Related]
15. Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.
Yang D; Dai R; Zhang Q; Fang P
Saudi J Biol Sci; 2018 Jul; 25(5):888-894. PubMed ID: 30108437
[TBL] [Abstract][Full Text] [Related]
16. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
19. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma.
Wang C; Jiang M; Hou H; Lin Q; Yan Z; Zhang X
Oncol Lett; 2018 Nov; 16(5):5607-5614. PubMed ID: 30344715
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review.
Shi C; Feng Y; Zhang LC; Ding DY; Yan MY; Pan L
BMC Cancer; 2018 Mar; 18(1):338. PubMed ID: 29587657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
